Kindred Bio Announces Initiation of Pivotal Clinical Study for CereKin™CereKin™ (KIND-001), a novel oral cytokine inhibitor, is expected to be a major step forward in the treatment of dogs with arthritis.
SAN FRANCISCO - Aug. 6, 2013 - PRLog -- Kindred Biosciences, Inc. (Kindred Bio) announced today that it has initiated a pivotal clinical trial for CereKin™ (KIND-001) in dogs with osteoarthritis. The trial is being conducted under a protocol concurrence negotiated with the FDA and, if positive, is expected to lead to the approval of CereKin™ by 2015.
CereKin™ is a potent downregulator of several cytokines, including tumor necrosis factor (TNF). It is a member of a novel class of anti-inflammatory agents and is free from the side effects typically associated with NSAIDs such as gastric ulceration, renal toxicity, or hepatic toxicity. It has also demonstrated, in several studies, the potential to delay the progression of osteoarthritis. Richard Chin, Chief Executive Officer of Kindred Bio, stated, “Initiating our first multicenter, clinical field study is a major milestone for Kindred Bio. We look forward to the day when we can bring this important drug to market and help our patients in need.” About Kindred Bio “Best Medicines for Our Best Friends” www.kindredbio.com Kindred Bio is a leading veterinary biotechnology company, focused on developing breakthrough therapies for dogs, cats, and horses. Founded by industry veterans formerly from Genentech and Elan Pharmaceuticals who have experience developing antibody drugs such as Lucentis®, Tysabri®, Xolair®, and Rituxan®, Kindred Bio is committed to bringing the very best science and medicine to companion animals. Forward-Looking Statements Forward-looking statements in this news release involve inherent risks and uncertainties and a number of important factors could cause actual results to differ materially from those contained in such forward-looking statements. These factors include, but are not limited to uncertainties associated with: drug development and regulatory review process, scientific discovery process, competition, pricing environment, financing, intellectual property, and evolution of the companion animal market. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date. Trademark Acknowledgements Lucentis® is a registered trademarks of Genentech, Inc. Rituxan® is a registered trademark of Biogen Idec Inc. Xolair® is a registered trademark of Novartis AG Corporation. Tysabri® is a trademark of Elan Pharmaceuticals, Inc. Contact Denise Bevers Kindred Bio denise.bevers@ (650) 701-7908 End
Page Updated Last on: Aug 06, 2013
|
Account Phone Number